Literature DB >> 19928858

Displacement assay for the detection of stabilizers of inactive kinase conformations.

Sabine Klüter1, Christian Grütter, Tabassum Naqvi, Matthias Rabiller, Jeffrey R Simard, Vijaykumar Pawar, Matthäus Getlik, Daniel Rauh.   

Abstract

Targeting protein kinases with small molecules outside the highly conserved ATP pocket to stabilize inactive kinase conformations is becoming a more desirable approach in kinase inhibitor research, since these molecules have advanced pharmacological properties compared to compounds exclusively targeting the ATP pocket. Traditional screening approaches for kinase inhibitors are often based on enzyme activity, but they may miss inhibitors that stabilize inactive kinase conformations by enriching the active state of the kinase. Here we present the development of a kinase binding assay employing a pyrazolourea type III inhibitor and enzyme fragment complementation (EFC) technology that is suitable to screen stabilizers of enzymatically inactive kinases. To validate this assay system, we report the binding characteristics of a series of kinase inhibitors to inactive p38alpha and JNK2. Additionally, we present protein X-ray crystallography studies to examine the binding modes of potent quinoline-based DFG-out binders in p38alpha.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19928858     DOI: 10.1021/jm901297e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Insights from free-energy calculations: protein conformational equilibrium, driving forces, and ligand-binding modes.

Authors:  Yu-Ming M Huang; Wei Chen; Michael J Potter; Chia-En A Chang
Journal:  Biophys J       Date:  2012-07-17       Impact factor: 4.033

2.  Discovery of a potential allosteric ligand binding site in CDK2.

Authors:  Stephane Betzi; Riazul Alam; Mathew Martin; Donna J Lubbers; Huijong Han; Sudhakar R Jakkaraj; Gunda I Georg; Ernst Schönbrunn
Journal:  ACS Chem Biol       Date:  2011-02-22       Impact factor: 5.100

Review 3.  Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia.

Authors:  Francesca Musumeci; Chiara Greco; Giancarlo Grossi; Alessio Molinari; Silvia Schenone
Journal:  Cancers (Basel)       Date:  2018-11-09       Impact factor: 6.639

4.  Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility.

Authors:  David M Thal; Kristoff T Homan; Jun Chen; Emily K Wu; Patricia M Hinkle; Z Maggie Huang; J Kurt Chuprun; Jianliang Song; Erhe Gao; Joseph Y Cheung; Larry A Sklar; Walter J Koch; John J G Tesmer
Journal:  ACS Chem Biol       Date:  2012-08-21       Impact factor: 5.100

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.